Ask AI
ProCE Banner Events

Share

Advances in Oral Targeted Therapies for HR+/HER2- Breast Cancer: Best Practices for Oncology Pharmacists

This webinar reviews oral targeted therapies for HR-positive/HER2-negative breast cancer, with emphasis on biomarker-driven treatment selection, adverse event monitoring, and pharmacist-led adherence/persistence strategies. Topics include PI3K/AKT pathway inhibitors, PARP inhibitors, CDK4/6 inhibitors, and oral estrogen receptor–targeting agents.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Who Should Attend

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with breast cancer.

Time and location

Tuesday, June 23, 2026

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Agenda

  • A Pharmacist’s Primer on Evidence-Based Management of HR+/HER2- Breast Cancer With Oral Targeted Therapies  
  • Maximizing Adherence/Persistence to New Oral Targeted Therapies With Effective AE Monitoring and Management  
  • Final Polling and Audience Q&A

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence in monitoring and managing adverse events related to oral targeted therapies to maximize treatment adherence/persistence and therapeutic benefit in patients HR-positive/HER2-negative breast cancer. 

Target Audience
This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with breast cancer. 

Learning Objectives
Upon completion of this event, participants should be able to:

  • Apply the latest safety and efficacy evidence for oral targeted therapies to clinical practice to individualize the management of patients with HR-positive/HER2-negative breast cancer
  • Collaborate with patients, caregivers, and the multidisciplinary team to use evidence-based approaches for monitoring and managing adverse events associated with oral targeted therapies for HR-positive/HER2-negative breast cancer
  • Support adherence/persistence to oral targeted therapies in patients with HR-positive/HER2-negative breast cancer through expert-recommended communication strategies, tools, and resources

Accreditation

CE Accreditation

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-005-L01-P has been assigned to this live application-based activity (initial release date May 19, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC.

ProCE, LLC

Supporter

Supported by an educational grant from AstraZeneca.

AstraZeneca

Contact Information

For customer support please click here.

Mailing Address:

 

Decera Clinical
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.